How to access Pluvicto from Pakistan, the cross-border treatment pathway, 2026

*Clinically reviewed by Reserve Meds AI Clinical and Regulatory Review (see /trust). Last reviewed 2026-05-13.

A Pakistani patient with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) in adults who have been treated with androgen receptor pathway inhibitor and taxane-based chemotherapy, with PSMA expression confirmed by an approved PSMA PET imaging agent may receive a recommendation for Pluvicto (lutetium Lu-177 vipivotide tetraxetan) from their treating medical oncologist with access to a PSMA PET imaging and radioligand-certified facility. Pluvicto is FDA-approved in the United States and manufactured by Novartis (Advanced Accelerator Applications). It is a PSMA-targeted radioligand therapy. This is important: Pluvicto is not a ready-to-ship pharmacy medicine. It is delivered as a specialty procedure at a certified treatment site. That makes the cross-border pathway materially different from a conventional named-patient drug import.

This guide explains how the pathway works, what documentation your specialist needs, indicative cost and timing, and where Reserve Meds fits in.

The clinical situation

Pluvicto is a PSMA-targeted radioligand therapy. Mechanism: a small-molecule conjugate that binds prostate-specific membrane antigen (PSMA) on prostate cancer cells and delivers lutetium-177 beta-particle radiation. Dosing: 7.4 GBq (200 mCi) by intravenous infusion every 6 weeks for up to 6 doses, per FDA labeling, administered at a radiopharmacy-certified site. Baseline workup per FDA labeling includes PSMA PET imaging confirmation, complete blood count, comprehensive metabolic panel, baseline renal function, prior taxane and androgen receptor pathway inhibitor exposure, and bone marrow status. Other important warnings include radiation exposure to patient and household, myelosuppression, renal toxicity, embryo-fetal toxicity, infertility, and second primary malignancies. Your specialist and the US treatment center will discuss the risk-benefit profile, the requirement for a certified site, and the practical logistics before initiating therapy.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

How does this work across borders?

Because Pluvicto is administered as intravenous infusion of a radiopharmaceutical at a certified site at a certified site under specific facility protocols, the standard cross-border access pathway is patient travel to a US certified center, not import of the product into Pakistan. DRAP does support named-patient drug imports, but PSMA-targeted radioligand therapy products are practically delivered via patient travel to a certified treatment facility under that facility's protocol.

Reserve Meds can help coordinate the referral arc to a US certified center, help your specialist assemble the referral package, and coordinate the family logistics around the multi-week stay. We do not perform the procedure, we do not manufacture the product, and we do not provide the infusion. Those are functions of the US treatment center under its FDA authorisation.

How the pathway works, step by step

1. Consultation with your treating specialist in Pakistan. The recommendation is clinical, based on diagnosis, prior workup, and fitness for the regimen.
2. Referral package to a US certified center. Pathology, imaging, prior-therapy summary, organ function panel, and infectious disease screening are assembled into a referral package.
3. US center evaluation. The US center reviews the package, accepts the referral (or asks for additional workup), and schedules the procedure.
4. Patient travel. The patient travels to the US center. Reserve Meds coordinates travel, accommodations, and caregiver presence where required.
5. Procedure and recovery. The certified center delivers Pluvicto under its FDA-authorised protocol with appropriate monitoring.
6. Post-procedure follow-up. The patient transitions to ongoing follow-up coordinated between the US center and the Pakistani specialist.

What documentation your specialist needs

Your specialist will typically need to assemble:

• A clinical summary letter confirming diagnosis, prior workup, and Pluvicto as the recommended next step
• Pathology and imaging reports relevant to the indication
• Organ function panel and other baseline labs aligned with FDA labeling
• Confirmation that the patient has a designated caregiver who can accompany them for the duration of US treatment
• A monitoring plan covering PSMA PET imaging report, radiopharmacy facility certification, and radiation safety briefing for patient and household

Reserve Meds provides a referral kit that bundles what US certified centers expect to see in a complete referral package for PSMA-targeted radioligand therapy cases.

Typical costs and indicative timing

Reserve Meds gives you a transparent reference range and an itemised quote at intake. As an illustrative composite case, the US cash-pay reference range for a single 7.4 GBq dose (treatment course is up to 6 doses) of Pluvicto sits in an indicative 2026 band of approximately USD 42,000 to 48,000. The treatment center facility and physician fees, baseline workup, complication management, and post-procedure follow-up add substantially more. Travel, accommodations, caregiver presence, and the multi-week stay are additional. Reserve Meds itemises each component in the delivered quote at intake.

Indicative timing from referral acceptance to the first procedure is typically 6 to 10 weeks (radiopharmaceutical logistics): time for the US center to review and schedule, plus patient travel logistics. Maintenance dosing then runs on the FDA-labeled schedule.

These cases require additional clinical and logistical vetting given the complexity and cost profile.

Where Reserve Meds fits in

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Pluvicto specifically, we provide:

• Referral coordination. We work with your Pakistani specialist to identify candidate US certified centers and route the referral package.
• Documentation. Referral package assembly aligned with US center intake requirements.
• Travel and logistics. Coordination of patient and caregiver travel, accommodation near the treatment center, and the multi-week stay.
• Concierge case lead. A named point of contact for the family across the full case arc.

We are a coordinator. We are not the prescriber, not a US treatment center, not the manufacturer, and not an oncology or rare disease provider. The US treatment center is the clinical entity under its FDA authorisation. Reserve Meds operates on cash-pay only and does not bill insurance.

Frequently asked

Is this legal? Yes. Patient travel to a US-certified treatment center is a long-established pathway used by international patients across many specialty programs. Reserve Meds operates as the coordination layer, not the clinical provider.

Can I receive Pluvicto locally? If a local certified program exists and your physician concludes it is appropriate for your case, that is typically the simpler pathway. Reserve Meds is most useful when the local option is not available, not stocked, or your case requires a US specialist evaluation.

Will my private health insurance cover this? Cash-pay is the default posture. Cash-pay is the default posture in Pakistan; some employer plans cover specialty imports case-by-case. We supply documentation for your submission but do not process insurance claims.

What if I cannot travel to the US? Then cross-border Pluvicto access via this pathway is not feasible, and your specialist should explore other locally available options. Reserve Meds will tell you that directly rather than charge for a service that cannot deliver.

Next step

These cases require additional clinical and logistical vetting.

---

Composite case examples. This content is for general information and does not constitute medical advice.